Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with p-STAT1/3 reduction in T-cells

March 1, 2021

Publication

Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with p-STAT1/3 reduction in T-cells

R. M. Brand, B. A. Moore, A. Zyhowski, A. Siegel, S. Uttam, E. J. Metter, J. Engstrom, R. E. Brand, N. Biswas, D. C. Whitcomb, D. G. Binion, M. Schwartz, I. McGowan

Am. J. Physiol. Gastrointest. Liver Physiol. 320(3):G396-G410

This study presents the development of a pre-clinical ex vivo system for testing efficacy and target engagement of therapeutics in inflammatory bowel disease using freshly obtained and well-characterized human colorectal tissue from patients with ulcerative colitis. Tofacitinib based JAK/STAT signaling inhibition was used to test the system. We performed the computational and statistical analyses.

https://doi.org/10.1152/ajpgi.00383.2020